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Original article
Biomarker-based treatment selection in early-stage rectal
cancer to promote organ preservation
K. J. Leong, A. Beggs, J. James, D. G. Morton, G. M. Matthews and S. P. Bach
School of Cancer Sciences, Vincent Drive, University of Birmingham, Birmingham B15 2TT, UK
Correspondence to: Dr G. M. Matthews (e-mail: G.M.Matthews@bham.ac.uk)
Background: Total mesorectal excision (TME) remains commonplace for T1–2 rectal cancer owing to
fear of undertreating a small proportion of patients with node-positive disease. Molecular stratification
may predict cancer progression. It could be used to select patients for organ-preserving surgery if specific
biomarkers were validated.
Methods: Gene methylation was quantified using bisulphite pyrosequencing in 133 unirradiated rectal
cancer TME specimens.KRASmutation andmicrosatellite instability status were also defined. Molecular
parameters were correlated with histopathological indices of disease progression. Predictive models
for nodal metastasis, lymphovascular invasion (LVI) and distant metastasis were constructed using a
multilevel reverse logistic regression model.
Results: Methylation of the retinoic acid receptor 𝛃 gene,RARB, and that of the checkpoint with forkhead
and ring finger gene, CHFR, was associated with tumour stage (RARB: 51⋅9 per cent for T1–2 versus 33⋅9
per cent for T3–4, P<0⋅001; CHFR: 5⋅5 per cent for T1–2 versus 12⋅6 per cent for T3–4, P= 0⋅005).
Gene methylation associated with nodal metastasis included RARB (47⋅1 per cent for N− versus 31⋅7
per cent for N+; P= 0⋅008), chemokine ligand 12, CXCL12 (12⋅3 per cent for N− versus 8⋅9 per cent for
N+; P=0⋅021), and death-associated protein kinase 1, DAPK1 (19⋅3 per cent for N− versus 12⋅3 per cent
for N+; P=0⋅022). RARB methylation was also associated with LVI (45⋅1 per cent for LVI− versus 31⋅7
per cent for LVI+; P= 0⋅038). Predictive models for nodal metastasis and LVI achieved sensitivities of
91⋅1 and 85⋅0 per cent, and specificities of 55⋅3 and 45⋅3 per cent, respectively.
Conclusion: This methylation biomarker panel provides a step towards accurate discrimination of
indolent and aggressive rectal cancer subtypes. This could offer an improvement over the current standard
of care, whereby fit patients are offered radical surgery.
Paper accepted 17 April 2014
Published online 23 July 2014 in Wiley Online Library (www.bjs.co.uk). DOI: 10.1002/bjs.9571
Introduction
Rectum-preserving surgery has been proposed with grad-
ual acceptance for early-stage tumours and for those down-
staged by neoadjuvant therapy1. Local excision, either
alone or combined with radiotherapy, cures the majority
of cases that appear confined to the bowel wall. How-
ever, even in this select group, recurrence rates as high
as 30 per cent following organ-preserving treatment have
been described2. Optimized organ preservation approaches
would benefit from the identification of high-risk tumour
characteristics other than the somewhat crude morpho-
metric, radiological and histological stratification currently
available3–5. Prediction of nodal metastasis by size or
imaging characteristics is an imprecise science, particu-
larly following neoadjuvant therapy6. The probability of
local recurrence after transanal endoscopic microsurgery
(TEMS) for early rectal cancer may be predicted based
upon tumour diameter, depth of invasion and adverse histo-
logical features7. This model provides practical reassur-
ance for individuals with a predicted low risk of recur-
rence (less than 5 per cent), where total mesorectal excision
(TME) has little to offer. As risk increases (10–25 per cent),
patients face a dilemma and must trade the prospect of
undertreatment or overtreatment. In addition, these deter-
minants are not applicable to preoperative samples. Hence,
molecular signatures of good (or indeed poor) prognosis
accessible via tumour biopsies would be useful biomarkers
to stratify risk and inform organ-preserving decisions.
Early translational research8,9 has shown that patients
with tumours expressing particular molecular profiles have
© 2014 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd.
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a poor prognosis. Epigenetic differences (for instance
DNA methylation) predict recurrence of early-stage rectal
cancer10. Two patterns of abnormal DNA methylation are
observed in colorectal cancer: genome-wide hypomethy-
lation or localized hypermethylation at or near tumour
suppressor gene promoters11. It has been suggested12 that
the loss of function of classical tumour suppressor genes
by promoter hypermethylation is more common than by
mutation. Various methylation-related mechanisms that
trigger genetic changes and contribute to tumorigene-
sis have been described13–16. Biomarkers of tumour pro-
gression show promise in distinguishing indolent and
aggressive cancer in other organs17,18. Prognostic models
incorporating multiple biomarkers have been described in
breast19 and hepatocellular20 cancers. The present authors
have shown previously21 that hypermethylation of two
or more genes in rectal tumours can be associated with
early-stage disease. The objective of this retrospective
study was to refine the prognostic utility of rectal cancer
biomarkers in order to aid selection of appropriate patients
for organ-preserving strategies1,22.
Methods
Samples
Rectal tumour samples were taken from two patient groups
treated with TME at the University Hospitals of Birming-
ham. The first group was obtained from a tissue bank of
colorectal cancer specimens from patients treated between
2001 and 2004. Samples from the core of the resected
tumour had been flash-frozen by the operating sur-
geon immediately after surgery. Histologically confirmed
tumour-free samples (5 cm or more from the tumour edge)
were frozen for paired analysis. The second group was
obtained from histopathology archives of formalin-fixed,
paraffin-embedded rectal tumour sections from patients
treated between 2005 and 2010. Patients who had received
neoadjuvant chemoradiotherapy, or had a family or per-
sonal history of inflammatory or malignant bowel disease
were excluded. Ethical approval was obtained from the
Black Country Research Ethics Committee.
Macrodissection, DNA extraction and bisulphite
treatment
Genomic DNA extraction of fresh-frozen tissues was
performed using the DNeasy® Blood & Tissue Kit (QIA-
GEN, Crawley, UK) according to the manufacturer’s
instructions. Approximately 2mm3 tissue was used, and
purified genomic DNA was made up to a final volume
of 200 μl. DNA extracts were quantified and assessed
for quality using a NanoDrop 1000 Spectrophotometer
(Thermo Scientific, Loughborough, UK). Bisulphite
modification of 1 μg genomic DNA was performed using
the EpiTect® Bisulfite Kit (QIAGEN), according to the
manufacturer’s instructions.
Paraffin-embedded blocks were sectioned at 5 μm thick-
ness and mounted on glass slides. A reference slide for
each sample was stained with haematoxylin and eosin.
Areas containing more than 80 per cent of tumour
tissue were marked to guide sampling from adjacent,
non-haematoxylin and eosin-stained sections. DNA
extraction and bisulphite treatment of formalin-fixed,
paraffin-embedded tissues was performed using the
EpiTect® Plus Bisulfite Kit (QIAGEN), according to the
manufacturer’s instructions.
Bisulphite pyrosequencing
Oestrogen receptor 1 gene (ESR1) and unc-5 homologue
C gene (UNC5C) assays were purchased from QIAGEN.
The glutathione S-transferase pi 1 gene (GSTP1) primer
sequences and polymerase chain reaction (PCR) con-
ditions are available at the PyroMark™ assay database
(http://techsupport.pyrosequencing.com). Retinoic acid
receptor β (RARB), long interspersed nucleotide element
1 (LINE-1) and adenomatous polyposis coli (APC) gene
assays have been described previously21,23,24. Primers for
the remaining nine assays were designed using the Meth-
Primer software (http://www.urogene.org/methprimer/
index1.html). Primer sequences and the PCR annealing
temperatures (Tm), and the number of cytosine–guanine
Table 1 Patient demographics and clinicopathological
characteristics of samples used
Adjacent tissue
(n=64)
Rectal cancer
(n=133)
Age (years)* 71 (33–89) 70 (31–92)
Sex ratio (M : F) 42 : 22 78 : 55
TNM stage
I 32 (24⋅1)
II 43 (32⋅3)
III 41 (30⋅8)
IV 17 (12⋅8)
Tumour size (mm)* 40 (9–110)
Vascular invasion
No 87 (65⋅4)
Yes 46 (34⋅6)
Degree of differentiation
Well 12 (9⋅0)
Moderate 115 (86⋅5)
Poor 6 (4⋅5)
Values in parentheses are percentages unless indicated otherwise; *values
are median (range). TNM, tumour node metastasis classification.
© 2014 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2014; 101: 1299–1309
on behalf of BJS Society Ltd.
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Fig. 1 Methylation levels of a APC, b CDH13, c CHFR, d RARB and e ESR1 genes in matched adjacent tissues and rectal cancers.
Horizontal bars represent median methylation levels. a–e P< 0⋅001 (2-tailed Wilcoxon signed rank test)
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Fig. 2 Methylation levels of a CXCL12, b DAPK1, c UNC5C, dMINT3, eMINT17 and f LINE-1 genes in matched adjacent tissues and
rectal cancers. Horizontal bars represent median methylation levels. a,c–f P< 0⋅001, b P= 0⋅007 (2-tailed Wilcoxon signed rank test)
© 2014 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2014; 101: 1299–1309
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Fig. 3 Methylation levels of a RARB and b CHFR genes, stratified according to depth of invasion. Horizontal bars represent median
methylation levels. a P< 0⋅001, b P= 0⋅005 (2-tailed Mann–Whitney U test)
nucleotide (CpG) sites examined are shown in Table S1
(supporting information). PCR for assays designed
in-house was performed using 1 μl bisulphite-treated
DNA, 5 pmol forward and reverse primers, 5 μl 10×
buffer, 1.5 μl 50-mmol/l magnesium chloride, 2⋅5mmol
of each dNTP and 1⋅5 units IMMOLASE™ DNA poly-
merase (Bioline, London, UK), made up to 50 μl with
sterile distilled water. The PCR conditions were: 95∘C
for 10min; 45 cycles of 95∘C for 20 s, Tm for 20 s and
72∘C for 30 s; and final extension at 72∘C for 5min. PCR
for the remaining assays was performed according to
either the manufacturer’s instructions or published proto-
cols (LINE-1). Negative water controls were included to
ensure no contamination.
Some 5 μl PCR products were analysed on a 1 per cent
agarose gel before pyrosequencing. Remaining PCR prod-
ucts were captured on streptavidin-coated beads, denatured
and washed, followed by the addition of sequencing primer.
Pyrosequencing was performed using PyroMark™ Gold
Q96 reagents on a PyroMark™ Q96 ID machine (QIA-
GEN). Samples were repeated on different days to assess
reproducibility. Internal validation was performed using
bisulphite-treated unmethylated and methylated genomic
DNA (CpGenome™ Universal DNA; Merck–Millipore,
Watford, UK). The instrument software (Pyro Q-CpG™;
QIAGEN) automatically calculates the percentage methy-
lation at each CpG site in the assay by quantifying the
relative peak heights of thymine/cytosine. Methylation for
each gene was expressed as the median percentage methy-
lation across all CpG sites.
Analysis of KRAS mutation
KRAS mutational analysis at codons 12 and 13 was per-
formed using pyrosequencing, as described previously25,26.
PCR reactions of 50 μl were set up using a standard pro-
tocol of 40 cycles at Tm of 59∘C using 0.3 μl MyTaq™
(Bioline) enzyme. PCR products were processed and run
on the PyroMark™ Q96 ID machine. The software auto-
matically generates percentage values for codon 12 and
13 single-nucleotide polymorphisms. Nucleotide substitu-
tions greater than 2⋅5 per cent were considered indicative
of KRAS mutation.
Analysis of microsatellite instability status
Microsatellite instability (MSI) status was analysed using a
refined method of the ‘Bethesda panel’ of markers27. The
modified panel consists of mononucleotide repeat markers
NR-21, NR-24, NR-27, BAT-25 and BAT-26. Tumours
with instability at two or more markers were defined as
MSI-high, whereas tumours with single-marker instability
were designated as MSI-low.
Relevant marker sections were amplified in a 25-μl mul-
tiplex PCR reaction including 1 μl sample DNA (35 cycles,
Tm55∘C , 0⋅2 μlMyTaq™enzyme). Fragment analysis was
performed on an ABI 3730 machine (Life Technologies,
Paisley, UK). Microsatellite marker sizes were determined
using Peak Scanner™ software (Life Technologies).
© 2014 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2014; 101: 1299–1309
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Fig. 4 Methylation levels of a RARB, b CXCL12 and c DAPK1 genes, stratified according to nodal metastasis: N−, nodal metastasis
absent; N+, nodal metastasis present. Horizontal bars represent median methylation levels. a P= 0⋅008, b P= 0⋅021, c P= 0⋅022
(2-tailed Mann–Whitney U test)
Statistical analysis
Statistical significance between groups was determined
using a Wilcoxon signed rank test for paired variables,
Mann–Whitney U test for unpaired continuous variables,
and Fisher’s exact test for categorical variables. P< 0⋅050
was considered statistically significant.
To design a predictive model using percentage methy-
lation of individual CpGs for each gene of interest, a
two-step logistic regression model was undertaken using
Stata® version 12.1 (StataCorp LP, College Station,
Texas, USA). This was done to predict lymph node
status, lymphovascular invasion (LVI) and distant metas-
tasis – histopathological parameters considered to be
associated with adverse patient outcomes. In the first step,
a reverse stepwise logistic regression model was performed
using CpGs in each gene as independent variables. The
threshold for significance was set at P< 0⋅100; significant
CpGs were taken forward into the next stage, where
these CpGs were entered into a reverse stepwise logis-
tic regression model as independent variables, with the
© 2014 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2014; 101: 1299–1309
on behalf of BJS Society Ltd.
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Fig. 5 Methylation levels of a RARB, b CDH13 and c CXCL12 genes, stratified according to distant metastasis: M−, distant metastasis
absent; M+, distant metastasis present. Horizontal bars represent median methylation levels. a P< 0⋅001, b P= 0⋅027, c P= 0⋅018
(2-tailed Mann–Whitney U test)
significance threshold for removal from the model set at
P< 0⋅100. MSI status and KRAS mutation status were also
entered into the model. The fit of the model was mod-
elled using the area under the curve (AUC) statistic and
a model was considered a good predictor when the AUC
was above 0⋅70. Goodness-of-fit testing was carried out
using standard residuals plots and the Hosmer–Lemeshow
test (with P< 0⋅100 indicating an inadequate model).
Model threshold for prediction was set pragmatically,
aiming to maximize sensitivity as close as possible to
90 per cent or above, and keeping specificity close to
50 per cent or above, on the basis that high-frequency
detection of adverse features was more important than
inclusion of patients without these features within the
cohort.
Results
Clinical and pathological data are summarized in Table 1.
Gene-specific hypermethylation was observed in rec-
tal cancer, compared with matched adjacent normal
mucosa (Figs 1 and 2; Fig. S1, supporting information).
© 2014 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2014; 101: 1299–1309
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Fig. 6 Methylation levels of a RARB and b CHFR genes, stratified according to a lymphovascular invasion (LVI; absent or present) and b
tumour size (less than, or greater than or equal to the median tumour size of 40mm). Horizontal bars represent median methylation
levels. a P= 0⋅038, b P= 0⋅011 (2-tailed Mann–Whitney U test)
Table 2 Biomarker model of genes associated with
histopathological features of disease progression
Histopathological feature Genes
Lymphovascular invasion CDH1, CDH13, MINT3
Lymph node metastasis CDH1, CDH13, MINT3, CXCL12,
RARB, APC
Distant metastasis CDH1, MINT3, CXCL12, RARB,
ESR1, CHFR
As expected, the methylation level of LINE-1, a marker
of global methylation, was lower in rectal cancer (Fig. 2).
Median percentage methylation was calculated for each of
15 genes for analysis of association with tumour stage and
pathology variables (Figs 3–6). Early-stage (pathological
tumour (pT) 1–2) and node-negative tumours had higher
median percentage methylation for RARB (Figs 3 and 4).
Larger tumours (median diameter 40mm or more) had
higher methylation levels of checkpoint with forkhead
and ring finger gene, CHFR (Fig. 6), as did more advanced
lesions (pT3–4). Node-negative tumours also exhibited
increased methylation levels of chemokine ligand 12 gene
(CXCL12) and death-associated protein kinase 1 gene
(DAPK1) compared with node-positive tumours (Fig. 4).
Tumours with either LVI or distant metastasis were asso-
ciated with lower methylation values of RARB (Figs 5 and
6). In addition, tumours with organ secondaries were asso-
ciated with less methylation of cadherin 13 gene, CDH13,
and CXCL12 (Fig. 5).
One-third of rectal cancers (44 of 133) carried the
KRAS mutation at codon 12 or 13. In contrast, only six
rectal tumours were found to be microsatellite unstable
(3 MSI-high and 3 MSI-low). Neither KRAS mutation
nor MSI status was associated with advanced disease in
univariable analysis.
Construction of a multivariable biomarker model
to predict disease progression in rectal cancer
Bisulphite pyrosequencing can quantify methylation at
multiple sequential CpGs, a feature that is absent in other
methylation platforms. Interrogation of individual CpGs,
rather than the mean across a locus, may identify the most
important or useful sites. A multilevel reverse stepwise
logistic regression model was constructed using individual
CpGs to identify genes associated with disease progres-
sion: LVI, lymph node metastasis and distant metastasis
(Table S2, supporting information).
For LVI, the model identified seven CpGs from three
genes as the most informative variables: CDH1 (sites 1, 2
and 4), CDH13 (sites 2 and 5) and methylated-in-tumour
3, MINT3 (sites 6 and 9) (Table 2). A model score was
developed by summating the percentage methylation of
each CpG, maintaining the direction of the coefficient.
The AUC for this model was 0⋅76 (95 per cent confidence
interval (c.i.) 0⋅68 to 0⋅84), and setting a cut-off score of
−20 gave a sensitivity of 85⋅0 per cent, specificity of 45⋅3
per cent with a positive predictive value of (PPV) of 62⋅5
© 2014 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2014; 101: 1299–1309
on behalf of BJS Society Ltd.
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Fig. 7 Receiver operating characteristic (ROC) curves constructed
for a lymphovascular invasion, b lymph node metastasis and c
distant metastasis. Area under ROC curve: a 0⋅76, b 0⋅76, c 0⋅82
per cent and a negative predictive value (NPV) of 74⋅0 per
cent (Fig. 7).
For lymph nodemetastasis, tenCpGs from six genes were
found to be significant:CDH1 (site 10), CDH13 (sites 7 and
8), MINT3 (sites 3 and 4), CXCL12 (sites 1 and 3), RARB
(site 6) and APC (sites 1 and 6) (Table 2). The AUC for the
model was found to be 0⋅76 (95 per cent c.i. 0⋅68 to 0⋅84),
and setting a cut-off score of −43 gave a sensitivity of 91⋅1
per cent, specificity of 55⋅3 per cent, PPV of 60⋅0 per cent
and NPV of 89⋅4 per cent (Fig. 7).
For distant metastasis, nine CpGs from six genes were
selected from the model: CDH1 (sites 2 and 6), MINT3
(sites 6 and 8), CXCL12 (sites 1 and 3), RARB (site 5), ESR1
(site 4) and CHFR (site 6) (Table 2). The AUC was 0⋅82 (95
per cent c.i. 0⋅73 to 0⋅91), and use of a cut-off score of −40
gave a sensitivity of 100 per cent and specificity of 51⋅3 per
cent, with a PPV of 100 per cent and a NPV of 90⋅6 per
cent (Fig. 7).
Discussion
Clinical outcomes for early rectal cancer are heterogeneous
and it is becoming clear that genetic events play a role in
determining such variation. Following on from previous
work21 showing an association between gene methylation
and pathological indices of disease progression, the present
study explored its feasibility as a predictive biomarker. The
results suggest that a multimarker methylation model is
needed to achieve high sensitivity for the prediction of dis-
ease progression. Single-gene testing is unlikely to be clin-
ically useful for prognosis; although MSI immunohisto-
chemistry is becoming routine and may confer prognostic
significance in certain scenarios28, it is notable thatmultiple
mutations are tested simultaneously.
The majority of early rectal cancers are node-negative,
and routine removal of the mesorectum may be
unnecessary. Deciding which patient is suitable for an
organ-preserving approach requires more refined prog-
nostic testing than is currently available. A pragmatic
approach was undertaken when determining the sensitivity
and specificity thresholds for the present predictive model.
The aim was to achieve a high sensitivity (90 per cent or
above) for patients at risk of disease progression with a
reasonable specificity (close to 50 per cent). By stratifying
50 per cent of patients as high risk and 50 per cent as
low risk, organ-preserving treatments could be offered
to the latter according to the profile of a small subset of
genes. Analysis of the methylome using next-generation
sequencing or gene array technologies may reveal addi-
tional markers to stratify risk further and tailor treatment
options (radiotherapy, local excision or radical surgery).
The present work has provided a step towards accurate
discrimination of indolent and aggressive rectal cancer sub-
types. The next stage is to evaluate the present biomarker
model in a prospective study. It can be tested as part of
the Transanal Endoscopic Microsurgery and Radiotherapy
in Early Rectal Cancer (TREC) study, which is already
© 2014 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2014; 101: 1299–1309
on behalf of BJS Society Ltd.
1308 K. J. Leong, A. Beggs, J. James, D. G. Morton, G. M. Matthews and S. P. Bach
evaluating the feasibility of randomization between con-
ventional surgery and a new organ-preserving protocol
of short-course preoperative radiotherapy with a 10-week
interval to TEMS29. Correlation of the molecular analysis
with clinical outcome data will be required to determine
the predictive accuracy of the present biomarker model.
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